Printer Friendly

Panel backs DDI despite uncertainties.

In an unusual move, an advisory panel to the Food and Drug Administration has recommended approving the AIDS drug didanosine even though clinical trials to establish the treatment's efficacy are still in progress. The panel, which made its recommendation two weeks ago, advised FDA to allow sales of didanosine - also called DDI for its chemical name, dideoxyinosine-for adults and children with AIDS who cannot tolerate zidovudine (AZT), the only other approved AIDS drug.

The panel based its decision primarily on data from "expanded access" trials of DDI, begun in 1989 (SN: 10/7/89, p. 231). Such trials allow researchers to collect some information on a drug's efficacy from seriously ill patients who receive the treatment outside statistically controlled trials. The advisory panel also considered data from two recent safety trials, one of which involved children (SN: 5/19/90, p.315; 1/26/91, p.55).

Unlike zidovudine, DDI does not cause anemia. However, it can cause pancreatitis, a potentially fatal swelling and inactivation of the pancreas. DDI's manufacturer, Bristol-Myers Squibb Co., reported last year that six of the roughly 9,000 patients participating in DDI clinical trials or expanded access programs had died of pancreatitis (SN: 3/17/90,p.165).

DDI's dangerous side effect, coupled with the paucity of efficacy data prompted concern among some members of the FDA advisory panel. Although University of Chicago statistician Paul Meier voted to recommend approval, he cautioned that the panel might be "ratcheting down" the usual standards for drug approval in order to speed a new AIDS treatment to market. One of the nine panelists voted against DDI approval.

Although FDA usually follows the recommendations of its advisory committees, the agency has not announced when it will make a final decision on DDI.
COPYRIGHT 1991 Science Service, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Food and Drug Administration panel recommends approving AIDS drug didanosine
Publication:Science News
Date:Aug 3, 1991
Words:293
Previous Article:Dancing DNA: tripping the light fantastic with heredity's master molecules.
Next Article:Experts urge funding for artificial heart.
Topics:


Related Articles
Proposal seeks wider access to AIDS drugs.
AIDS drug shows promise.
FDA broadens use of unproven AIDS drug.
AIDS predictors; can new laboratory markers speed the approval of AIDS drugs?
AIDS drug passes preliminaries.
AIDS drug sparks concern.
No survival bonus from early AZT.
AIDS drug finds a booster in FDA panel.
Drug resistance vexes treatment of AIDS.
New HIV drugs in the pipeline: drug companies have dozens of new anti-HIV drugs under study, with many advantages--and a few drawbacks--compared with...

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters